Jul 24, 2024 6:30am EDT Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Mar 27, 2024 8:00am EDT Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Aug 17, 2023 8:00am EDT Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Jun 21, 2023 7:00am EDT Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
May 22, 2023 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 21, 2023 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 10, 2023 7:00am EDT Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
